Navigation Links
Researchers Publish Preclinical Data on Reversing Peripheral Neuropathy
Date:1/17/2017

SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- An international team of researchers from UC San Diego School of Medicine and St. Boniface Hospital Albrechtsen Research Centre/University of Manitoba have identified potential treatments for peripheral neuropathy, an unmet health need affecting nearly one in 15 Americans. Published today in the Journal of Clinical Investigation, their results identify small molecule drugs with neuroprotective and neuroregenerative properties that prevent and reverse neuronal injury in animal models of metabolic, chemical and infection related peripheral neuropathy.

WinSanTor Inc. has exclusively licensed the technology from these institutes. Founded by this same team, WinSanTor was formed to accelerate the development of the first disease modifying treatments for peripheral neuropathy. Peripheral neuropathy manifests in people as weakness, pain, and/or numbness generally in the hands, arms, feet, and legs.

"Peripheral neuropathy is a major and often neglected health problem affecting hundreds of millions of people around the world, including a majority of diabetes patients," said Stanley Kim, co-founder and CEO of WinSanTor. "Today's medications focus on treating pain, one symptom of the disease. However, this is ineffective for the majority of patients, and there are no approved treatments to address nerve degeneration, the underlying cause of peripheral neuropathy."

The group showed that adult peripheral sensory neurons exhibit ongoing constraint of mitochondrial function and axon regenerative capacity via muscarinic receptors. Inhibiting muscarinic receptors protected peripheral neurons from ongoing metabolic or chemical injury and enhanced axonal regeneration. The paper further describes the role of mitochondrial function as an important target for treating peripheral neuropathy, and the potential for small molecule antagonists of muscarinic receptors to correct mitochondrial dysfunction.

"This data furthers our understanding of peripheral neuropathy and opens the possibility that the process of peripheral nerve degeneration may be therapeutically reversible," said Mr. Kim. "Moreover, utilizing existing drugs and their history as a base for developing a pipeline of a specific class of drugs to target mitochondrial dysfunction in peripheral neuropathy allows us to rapidly translate these findings to clinical studies, and to patients. At the end of the day, our focus is on delivering a new medicine that can really help patients with peripheral neuropathy."

WinSanTor and its founders have identified a lead compound, WST-057, a proprietary repurposing and reformulation of a well-characterized drug with an established safety history, WinSanTor has completed preclinical efficacy studies showing WST-057 prevents and reverses mitochondrial dysfunction, nerve fiber depletion, and sensory loss in several distinct animal models of peripheral neuropathy. WST-057 is now in Phase 1 clinical trials and plans to advance to proof-of-concept Phase 2 human trials later in 2017.  

WinSanTor has received financial support from the Canadian Institutes of Health Research (CIHR), the National Institutes of Health (NIH), the St. Boniface Hospital Foundation, and JDRF.  

About WinSanTor

WinSanTor is a clinical-stage biotechnology company focused on accelerating development of the first treatment to prevent and reverse peripheral neuropathy, beginning with diabetic peripheral neuropathy. Currently, there is no U.S. FDA-approved treatment for diabetic neuropathy, a condition that afflicts over 420 million worldwide who suffer from diabetes. WinSanTor's lead compound, WST-057, is a well-characterized previously-approved drug with an established safety history that has been used for many years against an unrelated indication. The company is also investigating the drug's potential to treat other common forms of peripheral neuropathy. WinSanTor was founded with the vision that recent scientific insights into the biological processes underlying degenerative diseases offer an unprecedented opportunity to discover and develop effective medicines. More at www.winsantor.com.

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications, Inc., jessica@litldog.com, +1.858.344.8091

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/researchers-publish-preclinical-data-on-reversing-peripheral-neuropathy-300392166.html


'/>"/>
SOURCE WinSanTor Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. One World Lab Unveils New Interactive Website for Life Science Researchers
2. SITC Seeking Applicants for Fellowships Supporting Cancer Immunotherapy Researchers
3. Rockland Immunochemicals, Inc. Partners with Alex’s Lemonade Stand Foundation to Support Early Career Childhood Cancer Researchers
4. Worcester Polytechnic Institute Researchers Build “Liquid Biopsy” Chip that Detects Metastatic Cancer Cells in a Drop of Blood
5. A Groundbreaking Discovery: Researchers Identify Gene Mutation Linked to Deadly Brain Aneurysms
6. TAMEST Recognizes Texas' Rising Star Researchers with 2017 Edith and Peter O'Donnell Awards
7. uBiome Doubles Research Grant to Award Two Microbiome Researchers up to $100,000 Each
8. Researchers Report Positive Response in Mesothelioma Patients on Experimental Drug, According to Surviving Mesothelioma
9. Researchers Say Mesothelioma Surgery Improves Survival, Regardless of Age, According to Surviving Mesothelioma
10. Swedish Researchers Find Familial Link Between Mesothelioma, Bladder, and Kidney Cancers, According to Surviving Mesothelioma
11. Researchers in Photonic Sensors, Fibre-Optic Communications Win Innovation Prizes at Photonics21 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced the three Winners and six Finalists of the 2017 Blavatnik Regional Awards ... the Blavatnik Family Foundation and administered by the New York Academy of Sciences ...
(Date:10/12/2017)... ... 2017 , ... AMRI, a global contract research, development and ... outcomes and quality of life, will now be offering its impurity solutions as ... regulatory requirements for all new drug products, including the finalization of ICH M7 ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):